Case Studies
Anonymized examples showing how our analysis identifies risks that standard due diligence misses.
A promising orthopedic device company built their FDA strategy around a predicate that was later recalled. Without clearance pathway, they ran out of runway.
Diagnostic company assumed $200+ reimbursement based on "comparable" tests. Actual CPT code paid $47. Investor negotiated 40% valuation reduction.
Surgical tool required 15 minutes of physician time per procedure with no reimbursement bump. Achieved less than 2% of target adoption.
Our clinical review identified a secondary indication with 3x the market size. Company pivoted, achieved FDA clearance in 11 months, acquired at 8x return.
Our methodology catches these issues before they become expensive lessons.
Schedule Assessment